| scholarly article | Q13442814 |
| P2093 | author name string | F Martinez | |
| C Legendre | |||
| G Canaud | |||
| P C Harris | |||
| J-M Correas | |||
| N Pallet | |||
| E Thervet | |||
| F Terzi | |||
| E Letavernier | |||
| C M Heyer | |||
| B Knebelmann | |||
| F Vrtovsnik | |||
| F Bienaimé | |||
| P2860 | cites work | Autosomal dominant polycystic kidney disease: the last 3 years | Q24656249 |
| TOR signaling in growth and metabolism | Q27860757 | ||
| A mitotic transcriptional switch in polycystic kidney disease | Q30498985 | ||
| Polycystic kidney disease | Q33709685 | ||
| The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease | Q34600282 | ||
| Measured GFR as a confirmatory test for estimated GFR. | Q34659317 | ||
| Transplantation of a cadaveric polycystic kidney in a patient with autosomal dominant polycystic kidney disease: long-term outcome | Q35835110 | ||
| A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 | Q36549183 | ||
| Sirolimus reduces polycystic liver volume in ADPKD patients | Q36667245 | ||
| Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease | Q37202501 | ||
| Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease | Q42927109 | ||
| Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort | Q44545045 | ||
| Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. | Q44732861 | ||
| Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease | Q45162599 | ||
| Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). | Q46749984 | ||
| Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function | Q46825310 | ||
| Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy | Q46826521 | ||
| Reduced exposure to calcineurin inhibitors in renal transplantation | Q46840533 | ||
| The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. | Q52549447 | ||
| The polycystic kidney donor | Q67966367 | ||
| Transplant of a polycystic kidney because of organ shortage | Q68756014 | ||
| Successful use of cadaver kidneys from diabetic donors for transplantation | Q68756022 | ||
| Development of polycystic disease in a kidney 10 years after transplantation | Q73253952 | ||
| Polycystic kidney patient as a cadaveric donor: is it appropriate? | Q73398135 | ||
| Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease | Q74245216 | ||
| Polycystic kidney disease | Q75230730 | ||
| Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease | Q80507407 | ||
| High sirolimus levels may induce focal segmental glomerulosclerosis de novo | Q80797353 | ||
| Volume progression in polycystic kidney disease | Q94478608 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autosomal dominant polycystic kidney disease | Q15443105 |
| autosomal dominant polycystic kidney | Q2732398 | ||
| P304 | page(s) | 1701-1706 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? | |
| P478 | volume | 10 |
| Q38987102 | ADPKD: clinical issues before and after renal transplantation. |
| Q55068368 | AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. |
| Q42082673 | Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease |
| Q47742358 | Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade |
| Q92019794 | Autosomal dominant polycystic kidney disease |
| Q38812543 | Clinical Trials and a View Toward the Future of ADPKD. |
| Q35917458 | Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease |
| Q54117927 | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. |
| Q89029564 | Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study |
| Q41897689 | Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. |
| Q27320627 | Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease |
| Q27001230 | Experimental therapies and ongoing clinical trials to slow down progression of ADPKD |
| Q36280381 | Folate-conjugated rapamycin slows progression of polycystic kidney disease |
| Q28299654 | Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling |
| Q33872509 | Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease |
| Q27303409 | Improved Structure and Function in Autosomal Recessive Polycystic Rat Kidneys with Renal Tubular Cell Therapy |
| Q41463847 | Inadvertent transmission of polycystic kidney disease in kidney transplantation |
| Q38067358 | Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease |
| Q33571758 | Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study |
| Q38002007 | Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications |
| Q36471777 | Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside |
| Q54540098 | Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. |
| Q38273327 | Novel therapeutic approaches to autosomal dominant polycystic kidney disease |
| Q38199755 | Pharmacological management of polycystic kidney disease |
| Q39320572 | Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin |
| Q33984585 | Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways |
| Q38220783 | Renal transplantation in autosomal dominant polycystic kidney disease |
| Q93134163 | The pathobiology of polycystic kidney disease from a metabolic viewpoint |
| Q90230633 | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges |
| Q38181599 | Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials |
| Q89288858 | Tuberous sclerosis complex |
| Q44767368 | mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open |
Search more.